A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma

  • Sabanathan, Dhanusha, (Associate Investigator)
  • Chapman, Nicola, (Other)
  • Butala, Radhika, (Other)
  • Gurney, Howard (Primary Chief Investigator)

Project: Other

Short titleAPOLLO
StatusActive
Effective start/end date16/05/1915/05/24